Akebia Therapeutics Inc (AKBA)
1.92
+0.06
(+2.95%)
USD |
NASDAQ |
Nov 08, 13:44
Akebia Therapeutics Revenue (TTM): 174.50M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 174.50M |
| March 31, 2024 | 187.22M |
| December 31, 2023 | 194.62M |
| September 30, 2023 | 194.21M |
| June 30, 2023 | 200.88M |
| March 31, 2023 | 270.87M |
| December 31, 2022 | 292.56M |
| September 30, 2022 | 294.46M |
| June 30, 2022 | 294.50M |
| March 31, 2022 | 221.04M |
| December 31, 2021 | 211.65M |
| September 30, 2021 | 210.01M |
| June 30, 2021 | 221.24M |
| March 31, 2021 | 258.47M |
| Date | Value |
|---|---|
| December 31, 2020 | 294.64M |
| September 30, 2020 | 308.16M |
| June 30, 2020 | 340.15M |
| March 31, 2020 | 350.81M |
| December 31, 2019 | 335.00M |
| September 30, 2019 | 325.30M |
| June 30, 2019 | 286.49M |
| March 31, 2019 | 234.48M |
| December 31, 2018 | 207.74M |
| September 30, 2018 | 238.45M |
| June 30, 2018 | 226.56M |
| March 31, 2018 | 206.29M |
| December 31, 2017 | 181.23M |
| September 30, 2017 | 92.20M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
174.50M
Minimum
Jun 2024
350.81M
Maximum
Mar 2020
255.53M
Average
258.47M
Median
Mar 2021
Revenue (TTM) Benchmarks
| Corcept Therapeutics Inc | 628.56M |
| Bioventus Inc | 555.06M |
| Eli Lilly and Co | 40.86B |
| NovaBay Pharmaceuticals Inc | 12.02M |
| Palatin Technologies Inc | -- |